Sartans in the treatment of high-risk hypertension: the abilities of candesartan

Abstract

This paper presents an overview of the literature on the treatment of arterial hypertension drugs that block the renin-angiotensin-aldosterone system (RAAS) – angiotensin receptor blockers ΙΙ (ARB), whose action is based on inhibition of the RAAS at the AII receptor. ARB candesartan (atakand), along with a strong long-term antihypertensive effect has organoprotective (causes regression of LVH has nephroprotection) antidiabetogennym effect, prevents the development of stroke. Clinical experience suggests candesartan, high efficiency and a good range of security among different categories of hypertensive patients with concomitant pathology, chronic heart failure, diabetes, obesity.

Keywords

• hypertension
• hypertension
• antihypertensive therapy
• blockade of the renin-angiotensin-aldosterone system
• angiotensin receptor blocker ii
• organoprotective
• regression of lvh
• candesartan
• atakand®